The first in vivo (live) study addressing the organism's root-level autonomous defense, repair, and regenerative mechanisms—which the Dr Biolyse^® technology aims to modulate via the Bioelectrical Epigenetic Programming (BEP) methodology—has been completed at the pre-clinical level on a bacterial sepsis model. Published in an international peer-reviewed scientific journal, this research provides a significant dataset for the pre-clinical validation of the technology's mechanistic principles of action.

The published pre-clinical data evaluate the respective biophysical triggering mechanism across three fundamental phases:

• Generation of the Response Profile Against the Pathology: The biophysical stimulation administered by the Dr Biolyse^® system autonomously activated the defense records within the mammalian organism's adaptive epigenetic system. It was observed that the process was not limited to a single symptom but initiated a holistic cellular defense response (antibacterial, anti-inflammatory, antioxidant, and cytoprotective).

• Functional Adequacy of the Generated Response Profile: In an aggressive sepsis model carrying a high risk of mortality (1×10⁹ CFU bacterial load), the triggered autonomous response was found to be functionally adequate in balancing the pathology. The suppression of systemic inflammation (cytokine storm) and the statistically significant pathogen clearance achieved demonstrated the regulatory capacity of the stimulation.

• Transition from Cellular Level to Systemic Homeostasis: The biophysical stimulation was shown to restore transmembrane dynamics and antioxidant balance at the cellular level, suppress damage (necrosis and infiltration) in vital organ systems at the tissue level, and stabilize blood gases and pH values at the systemic level, thereby guiding the organism to a state of general internal equilibrium (homeostasis).

The conducted study demonstrated no apparent adverse effects (side effects) at the tested dosimetry levels, constituting a significant translational milestone regarding the potential of Dr Biolyse^® technology to trigger the organism's autonomous adaptive mechanisms.

🔗 Access to the Scientific Publication: The full text of the research, which was designed as hypothesis-agnostic, can be accessed from the Scientific Publications section of our website.

Important Corporate and Legal Notice: This announcement is shared for the sole purpose of informing the public about academic developments published in a peer-reviewed scientific journal. The aforementioned study was conducted at the pre-clinical (animal) stage. In accordance with medical device regulations, it strictly does not constitute treatment advice, a medical claim, or serve a commercial marketing purpose.